Current Market Access to Avsola, Inflectra and Remicade

While biosimilars Avsola and Inflectra are picking up ground, Remicade is still more advantaged, holding covered or better status for 61% of all insured lives.

NOTE: Access that requires prior authorization and/or step therapy is represented by the abbreviation (PA/ST). 274.0 million lives are covered under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 7/12/21.

AIS Health Staff

AIS Health Staff

Related Posts

a-woman-touching-cellphone-screen
February 2

Economy, IRA, Pharma Competition May Impact Industry in 2023

Read More
businessman-analyzing-company-report-working-with-digital-augmented-reality-graphics
February 2

MMIT Payer Portrait: Blue Cross and Blue Shield of Louisiana

Read More
fda-approved-rubber-stamp-with-fda-and-pills-on-craft-paper
February 2

New Law Could Make Accelerated Approval Stricter, If FDA Enforces It

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today